DOP2021000176A - 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión - Google Patents
5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresiónInfo
- Publication number
- DOP2021000176A DOP2021000176A DO2021000176A DO2021000176A DOP2021000176A DO P2021000176 A DOP2021000176 A DO P2021000176A DO 2021000176 A DO2021000176 A DO 2021000176A DO 2021000176 A DO2021000176 A DO 2021000176A DO P2021000176 A DOP2021000176 A DO P2021000176A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- disorder
- dimethyltryptamine
- dmt
- meo
- depression
- Prior art date
Links
- 208000020401 Depressive disease Diseases 0.000 title abstract 2
- ZSTKHSQDNIGFLM-UHFFFAOYSA-N 5-methoxy-N,N-dimethyltryptamine Chemical compound COC1=CC=C2NC=C(CCN(C)C)C2=C1 ZSTKHSQDNIGFLM-UHFFFAOYSA-N 0.000 title 4
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000022266 body dysmorphic disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan composiciones para su uso en el tratamiento de un paciente que padece un trastorno mental en particular trastorno depresivo mayor, trastorno depresivo persistente, trastorno de ansiedad, trastorno de estrés postraumático, trastorno dismórfico corporal, trastorno obsesivo compulsivo, trastorno alimentario y abuso de sustancias psicoactivas. Se proporcionan además regímenes de dosificación para tratar estos trastornos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19158774 | 2019-02-22 | ||
| PCT/EP2020/054803 WO2020169850A1 (en) | 2019-02-22 | 2020-02-24 | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2021000176A true DOP2021000176A (es) | 2021-11-21 |
Family
ID=65529503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2021000176A DOP2021000176A (es) | 2019-02-22 | 2021-08-20 | 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20220071958A1 (es) |
| EP (3) | EP3927337B8 (es) |
| JP (2) | JP7598326B2 (es) |
| KR (1) | KR20210154966A (es) |
| CN (1) | CN114555078A (es) |
| AU (2) | AU2020225410B2 (es) |
| BR (1) | BR112021016153A2 (es) |
| CA (1) | CA3130406A1 (es) |
| CL (1) | CL2021002174A1 (es) |
| CO (1) | CO2021010882A2 (es) |
| CR (1) | CR20210437A (es) |
| DK (2) | DK3927337T3 (es) |
| DO (1) | DOP2021000176A (es) |
| EA (1) | EA202192318A1 (es) |
| EC (1) | ECSP21060868A (es) |
| ES (2) | ES2984438T3 (es) |
| FI (2) | FI4349407T3 (es) |
| HR (2) | HRP20240532T1 (es) |
| HU (2) | HUE066828T2 (es) |
| IL (1) | IL285537A (es) |
| LT (2) | LT4349407T (es) |
| MA (1) | MA55021B1 (es) |
| MD (1) | MD3927337T2 (es) |
| MX (2) | MX2021009941A (es) |
| NI (1) | NI202100080A (es) |
| PE (1) | PE20220015A1 (es) |
| PL (2) | PL3927337T3 (es) |
| PT (2) | PT3927337T (es) |
| RS (2) | RS66912B1 (es) |
| SI (2) | SI3927337T1 (es) |
| SM (1) | SMT202400154T1 (es) |
| WO (1) | WO2020169850A1 (es) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI4349407T3 (fi) | 2019-02-22 | 2025-06-02 | Gh Res Ireland Limited | 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon |
| US12377112B2 (en) | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| EP3753923A1 (en) | 2019-06-19 | 2020-12-23 | GH Research Limited | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent |
| KR20220082092A (ko) | 2019-11-07 | 2022-06-16 | 스몰 파마 엘티디 | 화합물 |
| EP3868364A1 (en) * | 2020-02-24 | 2021-08-25 | GH Research Limited | Aerosol comprising 5-methoxy-n,n-dimethyltryptamine |
| WO2021226416A1 (en) | 2020-05-08 | 2021-11-11 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| BR112022025306A2 (pt) | 2020-06-12 | 2023-02-28 | Beckley Psytech Ltd | Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina |
| EP4192451A4 (en) * | 2020-08-05 | 2024-08-14 | Universitätsspital Basel | METHOD OF ADMINISTERING INTRAVENOUS DMT FOR DMT-ASSISTED PSYCHOTHERAPY |
| AU2021328671A1 (en) | 2020-08-18 | 2023-02-16 | Cybin Irl Limited | Phenethylamine derivatives, compositions, and methods of use |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| JP7422474B2 (ja) * | 2020-08-28 | 2024-01-26 | サイビン ユーケー リミテッド | 注射用製剤 |
| EP4221682A2 (en) * | 2020-10-02 | 2023-08-09 | Cybin IRL Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| CN112138028A (zh) * | 2020-10-10 | 2020-12-29 | 南京中医药大学 | 蟾蜍色胺类物质在制备抗抑郁药物中的应用 |
| WO2022082058A1 (en) * | 2020-10-16 | 2022-04-21 | Eleusis Therapeutics Us, Inc. | Method of treatment by tryptamine alkaloids |
| WO2022117640A1 (en) * | 2020-12-01 | 2022-06-09 | Small Pharma Ltd | Inhalable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| US20220265582A1 (en) * | 2021-02-24 | 2022-08-25 | Universitätsspital Basel | Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy |
| CA3113414A1 (en) * | 2021-03-29 | 2022-09-29 | Mind Cure Health Inc. | Psychedelics protocol computer systems and methods |
| US20230136824A1 (en) | 2021-04-26 | 2023-05-04 | ATAI Life Sciences AG | N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof |
| JP2024517738A (ja) | 2021-04-26 | 2024-04-23 | アタイ セラピューティクス， インコーポレイテッド | 新規のｎ，ｎ－ジメチルトリプタミン組成物および方法 |
| EP4329759A4 (en) | 2021-04-30 | 2025-07-16 | Mind Medicine Inc | CRYSTALLINE FORMS OF LSD SALTS |
| JP2024517194A (ja) * | 2021-05-03 | 2024-04-19 | マインド メディシン， インコーポレイテッド | サイケデリック薬の用量を漸増する方法 |
| WO2022235927A1 (en) * | 2021-05-05 | 2022-11-10 | Gilgamesh Pharmaceuticals, Inc. | Novel tryptamines and methods of treating mood disorders |
| CA3218110A1 (en) | 2021-05-25 | 2022-12-01 | Majed Fawaz | New n,n-dimethyltryptamine salts and crystalline salt forms |
| AU2022287974A1 (en) | 2021-06-09 | 2024-01-04 | Atai Therapeutics, Inc. | Novel prodrugs and conjugates of dimethyltryptamine |
| JP7846211B2 (ja) | 2021-08-19 | 2026-04-14 | デフィニウム セラピューティクス ユーエス， インコーポレイテッド | 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤 |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159201A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Encapsulated microparticles and nanoparticles of dimethyltriptamines |
| EP4433049A1 (en) * | 2021-11-18 | 2024-09-25 | Cybin UK Ltd | Injectable and inhalable formulations |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| WO2023129956A2 (en) | 2021-12-30 | 2023-07-06 | ATAI Life Sciences AG | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| WO2023186837A1 (en) | 2022-03-27 | 2023-10-05 | GH Research Ireland Limited | Treatment of postnatal depression |
| IL315899A (en) | 2022-03-27 | 2024-11-01 | Gh Res Ireland Limited | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of social/emotional withdrawal or withdrawal |
| WO2023186834A1 (en) | 2022-03-27 | 2023-10-05 | GH Research Ireland Limited | Crystalline hydrobromide salt of 5-meo-dmt |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| AU2023427992A1 (en) | 2023-01-30 | 2025-09-18 | GH Research Ireland Limited | Treatment of mental disorders |
| AU2023427437A1 (en) | 2023-01-30 | 2025-09-18 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine for use in the treatment of mental disorders in breastfeeding mothers |
| GB202306256D0 (en) * | 2023-04-27 | 2023-06-14 | Beckley Psytech Ltd | 5-Methoxy-N,N-Dimethyltryptamine Formulations |
| WO2024251807A1 (en) * | 2023-06-08 | 2024-12-12 | Cybin Irl Limited | Companion animal treatments |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2025068714A1 (en) * | 2023-09-28 | 2025-04-03 | Beckley Psytech Limited | Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) |
| WO2025087962A1 (en) | 2023-10-23 | 2025-05-01 | Reconnect Labs Ag | Pharmaceutical formulations comprising 5-meo-dmt and their therapeutic uses |
| WO2025111597A1 (en) * | 2023-11-22 | 2025-05-30 | Gilgamesh Pharmaceuticals, Inc. | A treatment for patients with mood disorders using n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine or a pharmaceutically acceptable salt thereof |
| WO2026068951A1 (en) * | 2024-09-27 | 2026-04-02 | Beckley Psytech Limited | 5-methoxy-dmt for use in the treatment of depression |
| WO2026078143A1 (en) | 2024-10-09 | 2026-04-16 | GH Research Ireland Limited | Combinations of 5-meo-dmt with antidepressants for treating depression |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19803376C1 (de) | 1998-01-29 | 1999-10-14 | Markus Storz | Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten |
| US20030051728A1 (en) | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
| US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
| US20040127409A1 (en) | 2002-11-07 | 2004-07-01 | Milkhaus Laboratory, Inc. | Method of treatment of psychological conditions by administration of nerve growth factor |
| US20040234916A1 (en) | 2003-05-21 | 2004-11-25 | Alexza Molecular Delivery Corporation | Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
| ES2355983T3 (es) | 2006-08-01 | 2011-04-01 | STOBI GMBH & CO. KG | Balón de válvula para inhaladores . |
| CN103816150A (zh) * | 2014-03-14 | 2014-05-28 | 兰州理工大学 | 山蚂蝗生物碱单体成分的用途 |
| US20180021326A1 (en) * | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| US20200147038A1 (en) * | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| FI4349407T3 (fi) | 2019-02-22 | 2025-06-02 | Gh Res Ireland Limited | 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon |
-
2020
- 2020-02-24 FI FIEP24157425.0T patent/FI4349407T3/fi active
- 2020-02-24 MX MX2021009941A patent/MX2021009941A/es unknown
- 2020-02-24 RS RS20250591A patent/RS66912B1/sr unknown
- 2020-02-24 ES ES20710059T patent/ES2984438T3/es active Active
- 2020-02-24 RS RS20240531A patent/RS65706B1/sr unknown
- 2020-02-24 PL PL20710059.5T patent/PL3927337T3/pl unknown
- 2020-02-24 HU HUE20710059A patent/HUE066828T2/hu unknown
- 2020-02-24 ES ES24157425T patent/ES3031965T3/es active Active
- 2020-02-24 SM SM20240154T patent/SMT202400154T1/it unknown
- 2020-02-24 CA CA3130406A patent/CA3130406A1/en active Pending
- 2020-02-24 LT LTEP24157425.0T patent/LT4349407T/lt unknown
- 2020-02-24 WO PCT/EP2020/054803 patent/WO2020169850A1/en not_active Ceased
- 2020-02-24 EA EA202192318A patent/EA202192318A1/ru unknown
- 2020-02-24 DK DK20710059.5T patent/DK3927337T3/da active
- 2020-02-24 LT LTEPPCT/EP2020/054803T patent/LT3927337T/lt unknown
- 2020-02-24 EP EP20710059.5A patent/EP3927337B8/en active Active
- 2020-02-24 MA MA55021A patent/MA55021B1/fr unknown
- 2020-02-24 SI SI202030414T patent/SI3927337T1/sl unknown
- 2020-02-24 EP EP24157425.0A patent/EP4349407B1/en active Active
- 2020-02-24 PE PE2021001360A patent/PE20220015A1/es unknown
- 2020-02-24 CR CR20210437A patent/CR20210437A/es unknown
- 2020-02-24 DK DK24157425.0T patent/DK4349407T3/da active
- 2020-02-24 JP JP2021549427A patent/JP7598326B2/ja active Active
- 2020-02-24 US US17/431,626 patent/US20220071958A1/en not_active Abandoned
- 2020-02-24 FI FIEP20710059.5T patent/FI3927337T3/fi active
- 2020-02-24 HR HRP20240532TT patent/HRP20240532T1/hr unknown
- 2020-02-24 AU AU2020225410A patent/AU2020225410B2/en active Active
- 2020-02-24 BR BR112021016153-8A patent/BR112021016153A2/pt unknown
- 2020-02-24 SI SI202030619T patent/SI4349407T1/sl unknown
- 2020-02-24 PL PL24157425.0T patent/PL4349407T3/pl unknown
- 2020-02-24 MD MDE20211248T patent/MD3927337T2/ro unknown
- 2020-02-24 PT PT207100595T patent/PT3927337T/pt unknown
- 2020-02-24 PT PT241574250T patent/PT4349407T/pt unknown
- 2020-02-24 HR HRP20250590TT patent/HRP20250590T1/hr unknown
- 2020-02-24 KR KR1020217030215A patent/KR20210154966A/ko active Pending
- 2020-02-24 HU HUE24157425A patent/HUE071841T2/hu unknown
- 2020-02-24 EP EP24157388.0A patent/EP4353314A3/en active Pending
- 2020-02-24 CN CN202080030317.3A patent/CN114555078A/zh active Pending
-
2021
- 2021-08-11 IL IL285537A patent/IL285537A/en unknown
- 2021-08-16 CL CL2021002174A patent/CL2021002174A1/es unknown
- 2021-08-17 MX MX2025002567A patent/MX2025002567A/es unknown
- 2021-08-17 EC ECSENADI202160868A patent/ECSP21060868A/es unknown
- 2021-08-18 CO CONC2021/0010882A patent/CO2021010882A2/es unknown
- 2021-08-20 DO DO2021000176A patent/DOP2021000176A/es unknown
- 2021-08-20 NI NI202100080A patent/NI202100080A/es unknown
-
2024
- 2024-05-28 US US18/675,614 patent/US20240307350A1/en active Pending
- 2024-11-29 JP JP2024208392A patent/JP2025029035A/ja active Pending
-
2026
- 2026-01-30 AU AU2026200720A patent/AU2026200720A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000176A (es) | 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión | |
| CO2021010883A2 (es) | Composiciones que comprenden 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales | |
| MX2025007468A (es) | Composiciones y metodos para el manejo de trastornos | |
| MX2020011786A (es) | Oligomeros antisentido para tratamiento de afecciones y enfermedades. | |
| NI201700137A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicaciãn viral del dengue | |
| MX2017015186A (es) | Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t. | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| MX387839B (es) | Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea. | |
| MX2022014199A (es) | Usos y formulaciones de los cannabinoides. | |
| CO2021008187A2 (es) | Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica | |
| CL2021000882A1 (es) | Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia. | |
| EA201990976A1 (ru) | Новый способ профилактического лечения непроизвольной потери массы | |
| JOP20250311A1 (ar) | مثبطات tyk2 وتركيبات وطرق لها | |
| CL2022001167A1 (es) | Tratamiento de trastornos hepáticos | |
| BR112018009476A8 (pt) | regime de dosagem de plasminogênio para cicatrização de ferimentos | |
| MX2022005375A (es) | Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con neoplasias mieloproliferativas (nmp) con navitoclax. | |
| MX2023006855A (es) | Formas de dosificacion y usos terapeuticos de l-4-cloro quinurenina | |
| EA201892830A1 (ru) | Применение ксиборнола в качестве активного агента для лечения вирусных инфекций | |
| CL2022001476A1 (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso | |
| AR117329A1 (es) | Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica | |
| MX2022006630A (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso. | |
| MX385150B (es) | 3-beta-hidroxi-5-alfa-pregnan-20-ona para uso en tratamiento médico. | |
| Xu et al. | PS126. DAPK1 interaction with NMDA receptor NR2B subunit underlies the rapid antidepressant effect |